STAT+: Pharmalittle: We’re reading about a Novartis heart drug, BIO fighting a Trump program, and more
The FDA warned that GLP-1 drugs carry a potential risk for a rare but serious eye condition and required pharmaceutical companies to inform patients and doctors of the risk, STAT writes.
Key points
- Once again, we will note that our settings have changed to accept postcards and telegrams … The Food and Drug Administration approved a Bayer drug to reduce recurrence of stroke, making available the first in a novel class of medications that hold the promise of preventing blood clots more safely, STAT notes.
- … Novartis is largely abandoning an experimental drug analysts once considered a potential blockbuster after a study found it had little promise for preventing heart attacks and cardiovascular deaths, Bloomberg News notes.
- The growing field of research aimed at lipoprotein(a), a genetic risk factor for cardiovascular disease carried by 1 in 5 people, took a hit earlier this year when top-line Novartis results showed an experimental drug reduced Lp(a) but failed to lower serious outcomes.
The Biotechnology Innovation Organization is joining the legal fight against a Trump administration pilot program aimed at aligning drug prices in Medicare with prices charged in peer countries, STAT says.
Additional details
- GLOBE, which applies to Medicare Part B drugs administered in doctor offices, is not expected to have much impact because the administration exempted all but a handful of companies in return for their agreement to voluntary deals to charge Medicaid most-favored-nation prices.
- Secondary strokes are estimated to affect about 20% of people who have had a first stroke and can cause severe disability or death.
- District Court for the Northern District of California asserting the Global Benchmark for Efficient Drug Pricing demonstration, known as GLOBE, oversteps Medicare’s statutory authority.
- The condition, called non-arteritic anterior ischemic optic neuropathy, or NAION, is sometimes referred to as an “eye stroke” and is caused by insufficient blood flow to the optic nerve.
- Other drugmakers pursuing Lp(a) drugs include Amgen, Eli Lilly, and Silence Therapeutics, STAT adds.
How this summary was made: extractive summary — built from the sources' own reporting. It is drawn only from the reporting of the sources listed below — read the originals for full detail. How we summarize →
Advertisement
Every article behind this summary — 2 articles from 1 outlet
Get stories like this in your inbox.
Subscribe — it's freeOne free email at 6am — your topics, deduplicated, five minutes. No account, no paywall.